{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:36:38Z","timestamp":1792449398417,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["22213MFDS421"],"award-info":[{"award-number":["22213MFDS421"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04543-7","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:15:49Z","timestamp":1778544949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel mRNA-based multi-cytokine strategy to reprogram the peritoneal tumor microenvironment in ovarian cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Yu-Sun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Hyeon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahyun","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngran","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongje","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahyeon","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoung","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijeong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-In","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wookyeom","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Gyu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"4543_CR1","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409\u201336.","journal-title":"CA Cancer J Clin"},{"key":"4543_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4543_CR3","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"4543_CR4","first-page":"S111","volume":"131","author":"JS Berek","year":"2015","unstructured":"Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2015;131(Suppl 2):S111\u201322.","journal-title":"Int J Gynaecol Obstet"},{"key":"4543_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-2215-7-19","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19.","journal-title":"J Ovarian Res"},{"key":"4543_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139.","journal-title":"Nat Med"},{"key":"4543_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nm0303-269","volume":"9","author":"TA Waldmann","year":"2003","unstructured":"Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003;9:269\u201377.","journal-title":"Nat Med"},{"key":"4543_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","volume":"13","author":"G Trinchieri","year":"1995","unstructured":"Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251\u201376.","journal-title":"Annu Rev Immunol"},{"key":"4543_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.immunol.17.1.19","volume":"17","author":"TA Waldmann","year":"1999","unstructured":"Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19\u201349.","journal-title":"Annu Rev Immunol"},{"key":"4543_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23:90\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"4543_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407\u201320.","journal-title":"Nat Rev Immunol"},{"key":"4543_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417\u201326.","journal-title":"Mol Cell"},{"key":"4543_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680\u201390.","journal-title":"Clin Cancer Res"},{"key":"4543_CR14","doi-asserted-by":"crossref","unstructured":"Bechter O, Loquai C, Champiat S, Baurain J-F, Grob J-J, Utikal J et al. A phase I, first-in-human, dose-escalation, expansion trial of cytokine-encoding synthetic mRNA mixture alone or with cemiplimab in advanced solid tumors. Clin Cancer Res. 2025;31(12):2358-2369.","DOI":"10.1158\/1078-0432.CCR-24-1983"},{"key":"4543_CR15","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1517\/14712598.8.10.1495","volume":"8","author":"K Margolin","year":"2008","unstructured":"Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther. 2008;8:1495\u2013505.","journal-title":"Expert Opin Biol Ther"},{"key":"4543_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Kariko K, Tureci O. mRNA-based therapeutics\u2013developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759\u201380.","journal-title":"Nat Rev Drug Discov"},{"key":"4543_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12951-025-03196-2","volume":"23","author":"L Arrizabalaga","year":"2025","unstructured":"Arrizabalaga L, Di Trani CA, Fern\u00e1ndez-Sendin M, Bella \u00c1, Russo-Cabrera JS, Gomar C, et al. Intraperitoneal administration of mRNA encoding interleukin-12 for immunotherapy in peritoneal carcinomatosis. J Nanobiotechnol. 2025;23:113.","journal-title":"J Nanobiotechnol"},{"key":"4543_CR18","doi-asserted-by":"publisher","first-page":"2402966","DOI":"10.1002\/adhm.202402966","volume":"14","author":"B Marwedel","year":"2025","unstructured":"Marwedel B, De May H, Anderson L, Medina LY, Kennedy E, Flores E, et al. TLR agonist nano immune therapy clears peritoneal and systemic ovarian cancer. Adv Healthc Mater. 2025;14:2402966.","journal-title":"Adv Healthc Mater"},{"key":"4543_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersdorfer","year":"2019","unstructured":"Baiersdorfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids. 2019;15:26\u201335.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4543_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41541-025-01287-7","volume":"10","author":"A Oh","year":"2025","unstructured":"Oh A, Lee S, Park HJ, Yoon S, Ha D, Lee J, et al. Loop structure in poly(A) tail of mRNA vaccine enhances antigen translation efficiency and mRNA stability. NPJ Vaccines. 2025;10:234.","journal-title":"NPJ Vaccines"},{"key":"4543_CR21","doi-asserted-by":"publisher","first-page":"10692","DOI":"10.3390\/ijms231810692","volume":"23","author":"DL Almeida-Nunes","year":"2022","unstructured":"Almeida-Nunes DL, Mendes-Frias A, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Immune tumor microenvironment in ovarian cancer ascites. Int J Mol Sci. 2022;23:10692.","journal-title":"Int J Mol Sci"},{"key":"4543_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","volume":"20","author":"JW Leong","year":"2014","unstructured":"Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transpl. 2014;20:463\u201373.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4543_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molimm.2017.06.025","volume":"88","author":"E Lusty","year":"2017","unstructured":"Lusty E, Poznanski SM, Kwofie K, Mandur TS, Lee DA, Richards CD, et al. IL-18\/IL-15\/IL-12 synergy induces elevated and prolonged IFN-\u03b3 production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. Mol Immunol. 2017;88:138\u201347.","journal-title":"Mol Immunol"},{"key":"4543_CR24","doi-asserted-by":"crossref","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123-357ra123.","DOI":"10.1126\/scitranslmed.aaf2341"},{"key":"4543_CR25","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s13287-021-02655-5","volume":"12","author":"M Tarannum","year":"2021","unstructured":"Tarannum M, Romee R. Cytokine-induced memory-like natural killer cells for cancer immunotherapy. Stem Cell Res Ther. 2021;12:592.","journal-title":"Stem Cell Res Ther"},{"key":"4543_CR26","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","volume":"120","author":"R Romee","year":"2012","unstructured":"Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012;120:4751\u201360.","journal-title":"Blood"},{"key":"4543_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-20-1002","volume":"9","author":"MK Becker-Hapak","year":"2021","unstructured":"Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM, et al. A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy. Cancer Immunol Res. 2021;9:1071\u201387.","journal-title":"Cancer Immunol Res"},{"key":"4543_CR28","doi-asserted-by":"publisher","first-page":"TPS2696","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2696","volume":"42","author":"JJ Luke","year":"2024","unstructured":"Luke JJ, Kennedy LC, Sankar N, Menzies AM, Akkooi ACJv, Gonzalez M, et al. A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors. J Clin Oncol. 2024;42:TPS2696\u20132696.","journal-title":"J Clin Oncol"},{"key":"4543_CR29","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","volume":"26","author":"SL Hewitt","year":"2020","unstructured":"Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, et al. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clin Cancer Res. 2020;26:6284\u201398.","journal-title":"Clin Cancer Res"},{"key":"4543_CR30","doi-asserted-by":"publisher","first-page":"100055","DOI":"10.1016\/j.pscia.2024.100055","volume":"2","author":"PB Lokole","year":"2024","unstructured":"Lokole PB, Ngombe NK, Motomba DI, Safari JB, Mpuza MK, Krause RWM, et al. Preparation and characterization of micellar nanoparticles using crude saponins from five Congolese plant species. Pharm Sci Adv. 2024;2:100055.","journal-title":"Pharm Sci Adv"},{"key":"4543_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396\u2013401.","journal-title":"Nature"},{"key":"4543_CR32","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078\u201394.","journal-title":"Nat Rev Mater"},{"key":"4543_CR33","doi-asserted-by":"publisher","first-page":"eabi6899","DOI":"10.1126\/sciimmunol.abi6899","volume":"7","author":"D Xue","year":"2022","unstructured":"Xue D, Moon B, Liao J, Guo J, Zou Z, Han Y, et al. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Sci Immunol. 2022;7:eabi6899.","journal-title":"Sci Immunol"},{"key":"4543_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","volume":"79","author":"PJ Murray","year":"2017","unstructured":"Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541\u201366.","journal-title":"Annu Rev Physiol"},{"key":"4543_CR35","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3389\/fimmu.2019.01462","volume":"10","author":"A Viola","year":"2019","unstructured":"Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A. The metabolic signature of macrophage responses. Front Immunol. 2019;10:1462.","journal-title":"Front Immunol"},{"key":"4543_CR36","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3389\/fimmu.2019.01382","volume":"10","author":"X Guan","year":"2019","unstructured":"Guan X, Lu J, Sun F, Li Q, Pang Y. The molecular evolution and functional divergence of lamprey programmed cell death genes. Front Immunol. 2019;10:1382.","journal-title":"Front Immunol"},{"key":"4543_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1210\/me.2012-1387","volume":"28","author":"GW Robinson","year":"2014","unstructured":"Robinson GW, Kang K, Yoo KH, Tang Y, Zhu BM, Yamaji D, et al. Coregulation of genetic programs by the transcription factors NFIB and STAT5. Mol Endocrinol. 2014;28:758\u201367.","journal-title":"Mol Endocrinol"},{"key":"4543_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.15698\/cst2025.05.304","volume":"9","author":"A Dominguez-Lopez","year":"2025","unstructured":"Dominguez-Lopez A, Magana-Guerrero FS, Buentello-Volante B, Vivanco-Rojas O, Garfias Y. NFAT5: a stress-related transcription factor with multiple functions in health and disease. Cell Stress. 2025;9:16\u201348.","journal-title":"Cell Stress"},{"key":"4543_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1096\/fj.15-270256","volume":"30","author":"S Rother","year":"2016","unstructured":"Rother S, Bartels M, Schweda AT, Resch K, Pallua N, Nourbakhsh M. NF-kappaB-repressing factor phosphorylation regulates transcription elongation via its interactions with 5\u20193\u2019 exoribonuclease 2 and negative elongation factor. FASEB J. 2016;30:174\u201385.","journal-title":"FASEB J"},{"key":"4543_CR40","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.3390\/cancers12123818","volume":"12","author":"GA Rezniczek","year":"2020","unstructured":"Rezniczek GA, Buggisch J, Sobilo J, Launay A, Lerondel S, Le Pape A, et al. Establishment of a mouse ovarian cancer and peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers (Basel). 2020;12:3818.","journal-title":"Cancers (Basel)"},{"key":"4543_CR41","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/sj.bjc.6604803","volume":"99","author":"V Vassileva","year":"2008","unstructured":"Vassileva V, Moriyama EH, De Souza R, Grant J, Allen CJ, Wilson BC, et al. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Br J Cancer. 2008;99:2037\u201343.","journal-title":"Br J Cancer"},{"key":"4543_CR42","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.pscia.2024.100046","volume":"2","author":"Y Yao","year":"2024","unstructured":"Yao Y, Hu Y, Meng X, Feng F, Xu F, Wang G, et al. Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma. Pharm Sci Adv. 2024;2:100046.","journal-title":"Pharm Sci Adv"},{"key":"4543_CR43","doi-asserted-by":"publisher","first-page":"e1384","DOI":"10.1002\/ctm2.1384","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, et al. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med. 2023;13:e1384.","journal-title":"Clin Transl Med"},{"key":"4543_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","volume":"133","author":"RD Alvarez","year":"2014","unstructured":"Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, et al. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;133:433\u20138.","journal-title":"Gynecol Oncol"},{"key":"4543_CR45","doi-asserted-by":"publisher","first-page":"112156","DOI":"10.1016\/j.intimp.2024.112156","volume":"133","author":"S Vahidi","year":"2024","unstructured":"Vahidi S, Zabeti Touchaei A, Samadani AA. IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside. Int Immunopharmacol. 2024;133:112156.","journal-title":"Int Immunopharmacol"},{"key":"4543_CR46","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/14728222.2023.2287574","volume":"27","author":"A Cirella","year":"2023","unstructured":"Cirella A, Olivera I, Luri-Rey C, Bola\u00f1os E, Berraondo P, Melero I. Interleukin-18 in cancer immunology and immunotherapy. Expert Opin Ther Targets. 2023;27:1035\u201342.","journal-title":"Expert Opin Ther Targets"},{"key":"4543_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133\u201346.","journal-title":"Nat Rev Immunol"},{"key":"4543_CR48","doi-asserted-by":"crossref","unstructured":"Waldmann TA. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Investig Dermatol Symp Proc. 2013;16:S28-30.","DOI":"10.1038\/jidsymp.2013.8"},{"key":"4543_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8\u201327.","journal-title":"Immunol Rev"},{"key":"4543_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12672-024-01011-2","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Sun X, Tong Y. Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity. Discover Oncol. 2024;15:170.","journal-title":"Discover Oncol"},{"key":"4543_CR51","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.4049\/jimmunol.164.6.3330","volume":"164","author":"S Nakamura","year":"2000","unstructured":"Nakamura S, Otani T, Ijiri Y, Motoda R, Kurimoto M, Orita K. IFN-\u03b3-dependent and-independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol. 2000;164:3330\u20136.","journal-title":"J Immunol"},{"key":"4543_CR52","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1182\/blood.V96.4.1465","volume":"96","author":"WE Carson","year":"2000","unstructured":"Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G, et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-\u03b3 production and STAT-mediated signal transduction. Blood. 2000;96:1465\u201373.","journal-title":"Blood"},{"key":"4543_CR53","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.4049\/jimmunol.160.4.1742","volume":"160","author":"T Osaki","year":"1998","unstructured":"Osaki T, P\u00e9ron J-M, Cai Q, Okamura H, Robbins PD, Kurimoto M, et al. IFN-\u03b3-inducing factor\/IL-18 administration mediates IFN-\u03b3-and IL-12-independent antitumor effects. J Immunol. 1998;160:1742\u20139.","journal-title":"J Immunol"},{"key":"4543_CR54","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"4543_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"N Gong","year":"2021","unstructured":"Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16:25\u201336.","journal-title":"Nat Nanotechnol"},{"key":"4543_CR56","doi-asserted-by":"publisher","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","volume":"13","author":"C Hotz","year":"2021","unstructured":"Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13:eabc7804.","journal-title":"Sci Transl Med"},{"key":"4543_CR57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"4543_CR58","doi-asserted-by":"publisher","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","volume":"11","author":"SL Hewitt","year":"2019","unstructured":"Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs. Sci Transl Med. 2019;11:eaat9143.","journal-title":"Sci Transl Med"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04543-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:02:12Z","timestamp":1783573332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04543-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4543"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04543-7","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures involving animals were conducted in accordance with institutional guidelines for animal care and use and were approved by the Institutional Animal Care and Use Committee of the Catholic University of Korea (approval nos. CUK-IACUC-2022-031 and CUK-IACUC-2022-044). The study was conducted in compliance with the ARRIVE guidelines. No human participants, human data, or human tissues were used; therefore, informed consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"630"}}